HSBC Bank Plc : Form 8.5 (EPT/RI) - Deutsche Boerse AG

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
HSBC Bank Plc : Form 8.5 (EPT/RI) - Deutsche Boerse AG

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Name of exempt principal trader: HSBC BANK PLC
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree   Deutsche Boerse AG
(c) Name of the party to the offer with which exempt principal trader is connected: Deutsche Boerse AG
(d) Date dealing undertaken: 27 th December 2016
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A" Yes- London Stock Exchange Group Plc

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales   Total number of securities Highest price per unit paid/received (EUR) Lowest price per unit paid/received (EUR)
Tendered Ordinary Share   Purchase   4,737     78.71     77.91
Tendered Ordinary Share   Sale   4,737     78.71     77.91

(b)        Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (EUR)
         

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

3.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
    None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None
Date of disclosure: 28 th December 2016
Contact name: Ray Onrubia
Telephone number: 0207 088 2000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Hims & Hers Health Faces Revenue Challenges and Legal Issues

Updated Category News Views 246

Hims & Hers Revenue Challenges Amid Stock Decline In recent trading sessions, Hims & Hers Health reported notable stock fluctuations as the company unveiled a decline in revenue per customer linked to its customization of GLP-1 medications for weight loss. This announcement caused an almost 11% drop in the stock price. Impacts of Collaboration Termination This steep...

Continue Reading
Entrée Resources Reports Solid Results for Q3 2025

Updated Category News Views 166

Entrée Resources Ltd. Overview Entrée Resources Ltd. (TSX: ETG; OTCQB: ERLFF), a reputable Canadian mining company focused on the Oyu Tolgoi project, has announced its interim financial results for the third quarter of 2025. This announcement sheds light on its ongoing operations and future plans, emphasizing the company's significant role in one of the world's largest...

Continue Reading
Bucket List Wine Dinners Beckon to Los Angeles

Updated Category News Views 10

Sipping on the Extraordinary: LA Wine Soiree When was the last time you had a glass of wine that truly feels like you've unlocked a treasure chest? That's what LearnAboutWine.com is going for with their bucket list wine dinners in Los Angeles. Imagine tasting some of the world's most coveted bottles, all served with a level of polish that screams high-end dining. Led by...

Continue Reading
BioLife Solutions Enhances Growth Potential with $73 Million Sale

Updated Category News Views 68

BioLife Solutions Announces $73 Million Sale of SciSafe In a significant move aimed at reinforcing its strategic direction, BioLife Solutions, Inc. (NASDAQ: BLFS), a prominent player in the development and supply of cell processing tools and services for the cell and gene therapy market, has announced the sale of its biostorage subsidiary, SciSafe Holdings, Inc. The...

Continue Reading
Advancements in Universal Vaccine Development by Dx&Vx

Updated Category News Views 154

Innovative Pathway Towards a Universal COVID-19 Vaccine In the wake of a global resurgence of COVID-19, Dx&Vx (DXVX) is stepping up its efforts to develop a universal vaccine aimed at providing protection against all variants of the virus. With the recent acquisition of cutting-edge technology, this next-generation vaccine is set to attract significant global interest....

Continue Reading